Fiasp Cartridge

Fiasp (insulin aspart) is a fast-acting mealtime insulin used to help control blood sugar levels in adults and children with diabetes. It starts working within minutes after injection and is designed to reduce post-meal blood sugar spikes. Fiasp insulin cartridges are used with compatible insulin pens for convenient and precise dosing.

Benefits:

• Ultra-fast onset: Begins working in about 2 minutes.
• Helps reduce post-meal blood sugar spikes.
• Can be injected immediately before or up to 20 minutes after starting a meal.
• Provides flexibility for mealtime dosing.
• Compatible with insulin pen devices for easy administration.

Dosage:

• Individualized based on blood sugar levels, diet, and doctor’s recommendations.
• Typically taken before meals or within 20 minutes after starting a meal.
• Must be used with long-acting insulin or other diabetes medications, as prescribed.
• Rotate injection sites to prevent skin irritation.

Warnings and Precautions:

• Not for use in type 1 diabetes without long-acting insulin support.
• May cause low blood sugar (hypoglycemia); monitor blood sugar regularly.
• Do not use if the solution is cloudy or contains particles.
• Inform your doctor if you have kidney, liver, or heart disease.
• Avoid alcohol, as it may increase the risk of hypoglycemia.

Usage Instructions:

• Insert the cartridge into a compatible insulin pen.
• Check the insulin—it should be clear and colorless.
• Prime the pen as directed before injecting.
• Inject subcutaneously in the abdomen, thigh, or upper arm.
• Rotate injection sites with each dose.

Storage Information:

• Unopened cartridges: Store in the refrigerator (2°C to 8°C); do not freeze.
• In-use cartridges: Store at room temperature (below 30°C) for up to 28 days.
• Keep away from direct heat and sunlight.
• Do not use past the expiration date.

Common Side Effects:

• Low blood sugar (shakiness, sweating, dizziness).
• Injection site reactions (redness, swelling, itching).
• Weight gain.
• Mild headache or nausea.
• Skin thickening or lumps at the injection site (lipodystrophy).

More information about Fisap

• Product Monograph – Health Canada
• U.S. Food and Drug Administration Medication Guide